CLARITY PHARMACEUTICALS LIMITED (CU6)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

CU6

CU6 - CLARITY PHARMACEUTICALS LIMITED

FNArena Sector : Medical Equipment & Devices
Year End: June
GICS Industry Group : Pharmaceuticals, Biotechnology & Life Sciences
Debt/EBITDA: -0
Index: ASX200 | ASX300 | ALL-ORDS

LAST PRICE CHANGE +/- CHANGE % VOLUME

$2.24

17 Jun
2025

0.010

OPEN

$2.30

0.45%

HIGH

$2.37

2,748,748

LOW

$2.21

TARGET
$6.80

+1.90 change from previous day

 203.6% upside
OTHER COMPANIES IN THE SAME SECTOR
4DX . AT1 . AYA . BB1 . BRN . CAT . CBL . CGS . CMP . COH . CSX . CVB . CYC . EBR . EMV . EYE . FPH . IME . IMR . IPD . LDX . MX1 . NAN . ONE . PCK . PEB . PGC . PME . RMD . SOM . TRJ . UBI .
FNARENA'S MARKET CONSENSUS FORECASTS
CU6: 1
Title FY23
Actual		 FY24
Actual		 FY25
Forecast		 FY26
Forecast
EPS (cps) xxx - 15.5 - 17.7 xxx
DPS (cps) xxx 0.0 0.0 xxx
EPS Growth xxx N/A N/A xxx
DPS Growth xxx N/A N/A xxx
PE Ratio xxx N/A N/A xxx
Dividend Yield xxx N/A 0.0% xxx
Div Pay Ratio(%) xxx N/A N/A xxx

Dividend yield today if purchased 3 years ago: 0.00%

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

 0.00

Estimated Dividend Growth
(Average Of Past Three Years)

  %

Amount Invested

 $ 

Tell Me The Dividend After This Many Years
Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages
HISTORICAL DATA ARE ALL IN AUD
Copyright © 2025 FactSet UK Limited. All rights reserved
Title 201920202021202220232024
EPS Basic xxxxxxxxxxxxxxx-15.5
DPS All xxxxxxxxxxxxxxx0.0
Sales/Revenue xxxxxxxxxxxxxxx0.0 M
Book Value Per Share xxxxxxxxxxxxxxx46.9
Net Operating Cash Flow xxxxxxxxxxxxxxx-43.2 M
Net Profit Margin xxxxxxxxxxxxxxx-

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 201920202021202220232024
Return on Capital Employed xxxxxxxxxxxxxxx-39.29 %
Return on Invested Capital xxxxxxxxxxxxxxx-39.29 %
Return on Assets xxxxxxxxxxxxxxx-36.56 %
Return on Equity xxxxxxxxxxxxxxx-39.29 %
Return on Total Capital xxxxxxxxxxxxxxx-52.26 %
Free Cash Flow ex dividends xxxxxxxxxxxxxxx-43.7 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title 201920202021202220232024
Short-Term Debt xxxxxxxxxxxxxxx0 M
Long Term Debt xxxxxxxxxxxxxxx0 M
Total Debt xxxxxxxxxxxxxxx0 M
Goodwill - Gross xxxxxxxxxxxxxxx-
Cash & Equivalents - Generic xxxxxxxxxxxxxxx137 M
Price To Book Value xxxxxxxxxxxxxxx11.55

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title 201920202021202220232024
Capex xxxxxxxxxxxxxxx0.5 M
Capex % of Sales xxxxxxxxxxxxxxx-
Cost of Goods Sold xxxxxxxxxxxxxxx0 M
Selling, General & Admin. Exp & Other xxxxxxxxxxxxxxx56 M
Research & Development xxxxxxxxxxxxxxx46 M
Investments - Total xxxxxxxxxxxxxxx0 M

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

1.0

No. Of Recommendations

1
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Bell Potter

xx/xx/xxxx

1

xxxxxxxxxxx xxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Ord Minnett

18/03/2025

-1

Initiate coverage with a Buy

0.45%

Ord Minnett initiates coverage of Clarity Pharmaceuticals with a Buy rating and an $8.70 target price.

The broker highlights Clarity operates in the radiopharmaceutical sector with a portfolio of diagnostics and therapeutics.

The company’s SARbisPSMA pipeline is noted for its use of copper radioisotopes (64Cu and 67Cu), including manufacturing and geographic reach.

Ord Minnett emphasises the company's pipeline extends beyond prostate cancer to neuroblastoma, neuroendocrine tumours, and HER2-positive breast cancer.

Concerns over the supply of copper radioisotopes are addressed by management, who suggest there is sufficient raw material and production capacity to meet expected demand.

Clarity's upcoming trial results in 2025/26 could lift the target price by 30%, the analyst states.
Access Stockbroker Research History >
EXTRA COVERAGE
Display All Commentary

No. Of Recommendations

2

Please note: unlike Broker Call Report, BC Extra is not updated daily. The info you see might not be the latest. FNArena does its best to update ASAP.

BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Wilsons

xx/xx/xxxx

1

xxxxxxxxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Canaccord Genuity

11/06/2025

1

Buy

$6.74

200.89%

Canaccord Genuity highlights a positive topline readout from Clarity Pharmaceuticals’ Phase II Disco trial in GEP-NETs. 64Cu-Sartate is demonstrating 93-95% sensitivity in confirmed lesions, compared to just 5-7% 68Ga-Dotatate (NETSPOT), owned by Novartis.

The broker sees the results as a significant validation of Clarity’s copper-based platform, noting the superior image clarity linked to improved chelation technology and reduced copper leakage.

While GEP-NETs is not viewed as a large commercial opportunity, the outcome bolsters confidence in broader applications, suggest the analysts. This is particularly the case prior to a head-to-head prostate cancer diagnostic readout expected in 3Q25.

Canaccord  retains a Buy rating and a $6.74 target price.

FORECAST
Canaccord Genuity forecasts a full year FY25 dividend of 0.00 cents and EPS of minus -15.70 cents.
Canaccord Genuity forecasts a full year FY26 dividend of 0.00 cents and EPS of minus -23.20 cents.
Access Extra Coverage Research History >

CU6 STOCK CHART

FNArena News on CU6

1
Australian Broker Call *Extra* Edition – Jun 18, 2025

Jun 18 2025 - Daily Market Reports
2
In Case You Missed It – BC Extra Upgrades & Downgrades – 13-06-25

Jun 13 2025 - Weekly Reports
3
Rudi’s View: Amcor, GQG, IPH, Data#3 & Qualitas

Jun 12 2025 - Rudi's View
4
Australian Broker Call *Extra* Edition – Jun 11, 2025

Jun 11 2025 - Daily Market Reports
5
Rudi’s View: NextDC, QBE, Superloop & Woodside

Jun 05 2025 - Rudi's View

Latest Medical Equipment & Devices News

1
Fisher & Paykel Healthcare’s Tariffs Annoyance

Jun 04 2025 - Australia
2
ResMed’s Margin Expansion & Tariff Exemption

Apr 28 2025 - Australia
3
Trend Remains Up For Catapult International

Feb 18 2025 - Technicals
4
ESG Focus: Top ASX Companies, Superbugs & Hydrogen

Feb 07 2025 - ESG Focus
5
ResMed Shakes Off GLP-1 Scare

Feb 04 2025 - Australia
6
ResMed: Another Positive Quarterly Surprise?

Jan 30 2025 - Australia
7
The Trend Remains Pro Medicus’ Friend

Jan 16 2025 - Technicals
8
Diagnostic Imaging Radiates Opportunity

Dec 18 2024 - Small Caps
9
ResMed’s Bounce-Back Complete

Oct 29 2024 - Australia
10
Dr Boreham’s Crucible: Pro Medicus

Sep 04 2024 - Australia